Global clinical trials CellCarta operates a multinational network with facilities across Canada, the US, Belgium, Australia and China, enabling rapid global sample logistics, regulatory compliance, and localized support for complex translational research and clinical trials. Opportunity: position as the preferred CRO for multinational sponsors seeking consistent testing platforms, cross-border sample handling, and harmonized data across trial sites.

Digital pathology leadership Recent launch of the Global Digital Pathology and AI Consortium and integrations with AI pathology partners signal a strategic push into digital pathology and companion diagnostics. Opportunity: offer AI-driven biomarker discovery, image analysis SLAs, and CDx development support to pharma partners aiming for faster trial readouts and precision medicine strategies.

Companion diagnostics focus Appointment of a Chief Medical Officer and Head of Companion Diagnostics, plus partnerships with Pillar Biosciences and Sonic Healthcare USA, indicate a strong emphasis on CDx development and commercial readiness. Opportunity: upsell CDx development, bridging studies, regulatory alignment, and cross-functional support for sponsor-led CDx programs.

Strategic partnerships Recent collaborations with Leinco Technologies, RegAsk, Lunit, and SHUAS reflect a broad ecosystem approach covering proteomics, regulatory intelligence, AI pathology, and decentralized tumor profiling. Opportunity: propose integrated testing suites combining proteomics, regulatory intelligence, AI pathology, and decentralized lab capabilities to accelerate biomarker validation and regulatory submissions.

Regulatory and quality credibility Accreditations including CAP, CLIA, ISO15189, ISO27001 and ISO13485 underscore strong regulatory readiness and quality management. Opportunity: target large pharma and CROs needing compliant, audit-ready testing across multiple regions, offering risk mitigation and streamlined IDE/CDx regulatory pathways.